PATENT CLAIM ANALYSIS

Application Number: 15746182
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-03
Patent Classification: ["544", "008000"]

Abstract:
The invention provides a series of chlorobenzene substituted azaaryl compounds having activity in inhibiting cancer cell growth and low toxicity to normal cells. Particularly, the compounds of the invention have stronger inhibition effect on bladder cancer and liver cancer.

Claim (Index 13):
The pharmaceutical composition of  claim 12 , wherein the second therapeutic agent is a mitotic inhibitor (such as taxanes (preferably paclitaxel, docetaxel), vinca alkaloids (preferably, vinblastine, vincristine, vindesine and vinorelbine) and vepesid; an anthracycline antibiotic (such as doxorubicin, daunorubicin, daunorubicin, epirubicin, idarubicin, valrubicin and mitoxantrone); a nucleoside analog (such as gemcitabine); an EGFR inhibitor (such as gefitinib and erlotinib); an folate antimetabolite (such as trimethoprim, pyrimethamine and pemetrexed); cisplatin and carboplatin.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.23529
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15230700', '13391148', '11570966', '13575799', '15181903']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7388754399918976
- 35 USC 102 Novelty (BERT): 0.520501470677459
- Combined Prediction Score: 0.7170380430604538
- Mean Citation Score: 260.94092800000004
- Max Citation Score: 291.13596
- Similarity Product: 188.8256766934204

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test